1: Asser A, Hikima A, Raki M, Bergström K, Rose S, Juurmaa J, Krispin V, Muldmaa M, Lilles S, Rätsep H, Jenner P, Kõks S, Männistö PT, Taba P. Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers. J Neural Transm (Vienna). 2019 Nov 30. doi: 10.1007/s00702-019-02110-z. [Epub ahead of print] PubMed PMID: 31786692.
2: Asser A, Kõks S, Soomets U, Terasmaa A, Sauk M, Eltermaa M, Piip P, Ubhayasekera K, Bergquist J, Taba P. Acute effects of methcathinone and manganese in mice: A dose response study. Heliyon. 2019 Sep 20;5(9):e02475. doi: 10.1016/j.heliyon.2019.e02475. eCollection 2019 Sep. PubMed PMID: 31687570; PubMed Central PMCID: PMC6819833.
3: Ennok M, Sikk K, Haldre S, Taba P. Cognitive profile of patients with manganese-methcathinone encephalopathy. Neurotoxicology. 2019 Oct 31;76:138-143. doi: 10.1016/j.neuro.2019.10.007. [Epub ahead of print] PubMed PMID: 31678058.
4: Chong TT, Bonnelle V, Veromann KR, Juurmaa J, Taba P, Plant O, Husain M. Dissociation of reward and effort sensitivity in methcathinone-induced Parkinsonism. J Neuropsychol. 2018 Jun;12(2):291-297. doi: 10.1111/jnp.12122. Epub 2017 Apr 5. PubMed PMID: 28378511; PubMed Central PMCID: PMC6001457.
5: Juurmaa J, Menke RA, Vila P, Müürsepp A, Tomberg T, Ilves P, Nigul M, Johansen-Berg H, Donaghy M, Stagg CJ, Stepens A, Taba P. Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome. Brain Behav. 2016 Aug 18;6(11):e00539. eCollection 2016 Nov. PubMed PMID: 27843694; PubMed Central PMCID: PMC5102639.
6: Asser A, Kõks S, Snellman A, Haaparanta-Solin M, Arponen E, Grönroos T, Nairismägi J, Bergquist J, Soomets U, Piip P, Eltermaa M, Sauk M, Lindmäe H, Rinne JO, Taba P. Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese. Brain Res. 2016 Dec 1;1652:97-102. doi: 10.1016/j.brainres.2016.09.034. Epub 2016 Sep 28. PubMed PMID: 27693414.
7: Selikhova M, Tripoliti E, Fedoryshyn L, Matvienko Y, Stanetska H, Boychuk M, Komnatska I, Lees AJ, Sanotsky Y. Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse. Clin Neurol Neurosurg. 2016 Aug;147:71-7. doi: 10.1016/j.clineuro.2016.05.027. Epub 2016 May 31. PubMed PMID: 27310289.
8: Sikk K, Taba P. Methcathinone “Kitchen Chemistry” and Permanent Neurological Damage. Int Rev Neurobiol. 2015;120:257-71. doi: 10.1016/bs.irn.2015.02.002. Epub 2015 Mar 12. Review. PubMed PMID: 26070761.
9: Sikk K, Haldre S, Aquilonius SM, Asser A, Paris M, Roose Ä, Petterson J, Eriksson SL, Bergquist J, Taba P. Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up. Eur J Neurol. 2013 Jun;20(6):915-20. doi: 10.1111/ene.12088. Epub 2013 Jan 24. PubMed PMID: 23347399.
10: Sikk K, Kõks S, Soomets U, Schalkwyk LC, Fernandes C, Haldre S, Aquilonius SM, Taba P. Peripheral blood RNA expression profiling in illicit methcathinone users reveals effect on immune system. Front Genet. 2011 Aug 19;2:42. doi: 10.3389/fgene.2011.00042. eCollection 2011. PubMed PMID: 22303338; PubMed Central PMCID: PMC3268596.
11: Sikk K, Haldre S, Aquilonius SM, Taba P. Manganese-Induced Parkinsonism due to Ephedrone Abuse. Parkinsons Dis. 2011 Feb 17;2011:865319. doi: 10.4061/2011/865319. PubMed PMID: 21403909; PubMed Central PMCID: PMC3043321.
12: Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Askmark H, Danfors T, Sörensen J, Thurfjell L, Raininko R, Eriksson R, Flink R, Färnstrand C, Aquilonius SM. Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. Acta Neurol Scand. 2010 Apr;121(4):237-43. doi: 10.1111/j.1600-0404.2009.01189.x. Epub 2009 Dec 17. PubMed PMID: 20028341.
13: Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Zjablov G, Asser T, Aquilonius SM. Irreversible motor impairment in young addicts–ephedrone, manganism or both? Acta Neurol Scand. 2007 Jun;115(6):385-9. PubMed PMID: 17511846.